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Hematopoietic stem cells (HSCs) are widely used in transplantation therapy to treat a variety of blood diseases. The
success of hematopoietic recovery is of high importance and closely related to the patient’s morbidity and
mortality after Hematopoietic stem cell transplantation (HSCT). We have previously shown that SALL4 is a potent
stimulator for the expansion of human hematopoietic stem/progenitor cells in vitro. In these studies, we
demonstrated that systemic administration with TAT-SALL4B resulted in expediting auto-reconstitution and
inducing a 30-fold expansion of endogenous HSCs/HPCs in mice exposed to a high dose of irradiation. Most
importantly, TAT-SALL4B treatment markedly prevented death in mice receiving lethal irradiation. Our studies also
showed that TAT-SALL4B treatment was able to enhance both the short-term and long-term engraftment of human
cord blood (CB) cells in NOD/SCID mice and the mechanism was likely related to the in vivo expansion of donor
cells in a recipient. This robust expansion was required for the association of SALL4B with DNA methyltransferase
complex, an epigenetic regulator critical in maintaining HSC pools and in normal lineage progression. Our results
may provide a useful strategy to enhance hematopoietic recovery and reconstitution in cord blood transplantation
with a recombinant TAT-SALL4B fusion protein.
Keywords: Hematopoietic stem cell, Regeneration, Bone marrow transplantation, SALL4, Recombinant proteinBackground
Hematopoietic stem cell transplantation (HSCT) is a
type of stem cell therapy used to treat cancers such as
lymphoma and leukemia and other blood-related dis-
eases. However, there have been several limitations in
the use of bone marrow hematopoietic cell transplant-
ation. The primary limitation is that the donor pool is
limited by the need for at least partial HLA matching
and it usually takes time in finding a suitable donor [1].
Human umbilical cord blood (hUCB) is increasingly be-
ing used as an alternative source of hematopoietic stem/
progenitor cells (HSC/HPC) for allogeneic HSCT be-
cause of its rapid availability and less stringent require-
ment for HLA matching [2]. This is especially important
for minority patients and patients of mixed ethnicity,
where hUCB is a particularly attractive alternative donor* Correspondence: yupo.ma@stonybrook.edu
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stated.stem cell source. However, the absolute number of
hUCB HSC/HPC transplanted is much lower than bone
marrow or mobilized peripheral blood stem cells due
to the limited volume of hUCB. This leads to signifi-
cantly delayed engraftment and increased peri-transplant
complications [3-6]. One approach to overcome this
problem is to use two unrelated hUCB units for the
transplantation [7,8]. While this strategy improved adult
engraftment rates, it brought about worse GVHD (graft-
versus-host disease) [9]. In addition, of two or more
hUCBs transplanted into one recipient, it is usual for
only one of those multiple hUCBs infused in the patient
to be present [7,8,10]. There are multiple steps critical
for HSC/HPC engraftment in vivo including homing to
a niche, and then the seeded HSC/HPC expand and pro-
liferate, or engraft. Several other strategies that are being
explored to increase the engraftment include ex vivo ex-
pansion of hUCB HSC/HPC [11-14], increase of hUCB
HSC/HPC homing by CD26 inhibitor or SDF-1/CXCR4
regulation, and addition of third party mesenchymal
stem cells. However, there are still problems like risk of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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the process of ex vivo manipulation of hUCB involved in
these strategies [15]. The identification of agents to in-
crease hUCB engraftment by in vivo expansion of trans-
planted hUCB HSC/HPC without in vitro manipulation
is of significant therapeutic value.
Recently, we demonstrated that lentivirus expression
of SALL4 in human bone marrow HSC/HPC was able to
dramatically expand these cells and enhance their ability
of long-term engraftment in NOD/SCID mice [16-18].
In order to evaluate in vivo effect of SALL4 on
hematologic recovery and the engraftment of donor cell
in HSCT, we produced SALL4B protein in baculovirus
expression vector system (BEVS) and injected the pro-
tein into animals after iradiation or HSCT. In present
study, we successfully expressed and isolated a TAT-
SALL4B fusion protein carrying the protein transduction
domain of HIV transactivating protein (TAT) in BEVS
and showed the activity of the recombinant TAT-
SALL4B protein in vitro. In addition, the TAT-SALL4B
accelerates the regeneration of mouse bone marrow after
lethal or sub-lethal irradiation by in situ expansion of
the bone marrow HSC/HPC. In a transplantation model
where human cord blood CD34+ cells were introduced
into NOD/SCID mouse, TAT-SALL4B protein treatment
is able to augment both short-term and long-term
engraftment of human cells in the recipient mice. Our
results suggest the potential utility of recombinant TAT-
SALL4B protein as a stimulator for hematologic recov-
ery after myelosuppression and an enhancer for the
engraftment of cord blood cells in HSCT.
Results
Expression and purification of TAT-SALL4B fusion protein
Previously, we demonstrated that SALL4-tranduced hu-
man CD34+ cells were capable of rapid expansion
in vitro [16]. Protein transduction utilizing cell penetrat-
ing peptides (CPPs) can overcome many of the limita-
tions of lentiviral vectors. Therefore, we sought to
develop a CPP SALL4B fusion protein, TAT-SALL4B
expressed in a Sf9 insect cell system. We then tested the
impact of TAT-SALL4 on the growth of residual bone
marrow cells in vivo after ablation. The SALL4 stem
cell gene contains two alternatively spliced isoforms.
SALL4A is the large spliced variant and SALL4B is a
smaller variant with approximately half the full-length of
SALL4A. We focused our studies on SALL4B [16] be-
cause it is a shorter form and expressed a high level in
SF9 cells. In Figure 1a, the structures and functional
module of the SALL4B construct for the baculovirus ex-
pression system are shown. The full-length TAT-SALL4B
was expressed in baculovirus-infected Sf9 cells and puri-
fied using anti-Histidine (His) affinity chromatography
(Figure 1b-c).Functional activity of TAT-SALL4B fusion protein in vitro
In our earlier experiments utilizing SALL4B lentiviral
transduction [19], we showed that SALL4B could regu-
late the expression of multiple genes involved in the
self-renewal maintenance of human ES cells including
OCT4 and Nanog. In addition, SALL4B can regulate its
own promoter [20]. In order to test if TAT-SALL4B
bears similar functional activities, we constructed OCT4
and SALL4 luciferase promoter reporters into 293 T
cells, we found TAT-SALL4B protein could regulate
OCT4 and SALL4 promoter activities in a similar pat-
tern to that reported in previous study [19] (Figure 1d).
The TAT-SALL4B protein significantly upregulated
OCT4 and downregulated SALL4 promoter activities.
The luciferase activities also showed a dose dependent man-
ner in the presence of TAT-SALL4B protein. (Figure 1e).
We also tested the activity of TAT-SALL4B protein on the
growth of mouse bone marrow HSCs/HPCs enriched
by a combination of Lineage, c-Kit and Sca-1 magnetic
cell sorting. LSK (Lin-/c-Kit+/Sca-1+) cells were treated
with 20 nM TAT-SALL4B or BSA control. After 6 days
of culture, the total cell number was increased by ~40
fold in the TAT-SALL4B group as compared to only ~8
fold in the control (Figure 1f ).
Enhancing bone marrow recovery by TAT-SALL4B
As previously shown by our group, SALL4 expression is
seen in hematopoietic CD34 + [21], but not CD34- cells.
Markedly elevated levels of SALL4 were detected at the
early phase of bone marrow recovery after ablation and
expression levels were decreased as bone marrow cellu-
larity increased (Figure 2). This study indicates that up-
regulation of SALL4 may play a role of bone marrow
recovery. We then tested the impact of TAT-SALL4B on
the growth of residual bone marrow cells in vivo after
ablation. A series of experiments were carried out in
order to determine if the purified TAT-SALL4B fusion
protein had the ability to regenerate bone marrow pro-
duction in vivo. TAT-SALL4B protein, G-CSF, or PBS
was intraperitoneally injected into mice for seven con-
secutive days 24 hours after lethal irradiation (Figure 3a).
The dose of lethal irradiation (7 Gy, gamma-ray) admin-
istered to the mice was able to kill more than 99% of the
mouse bone marrow cells within two to three days. An
average of 2 × 107 whole bone marrow nucleated cells
was obtained from flushing out both tibias and femurs
from one wide type mouse. In the PBS group, the num-
ber of whole bone marrow cells per animal was 1.32 ±
0.21 × 105 at day 8 after irradiation. As consistent with
previous reports, G-CSF increased the number of whole
bone marrow cells by ~3-4 fold (4.51 ± 0.47 × 105) [22].
The increase was over 6-fold (7.91 ± 0.83 × 105) in the
SALL4B group compared to the PBS control. These data
suggest that SALL4B has a greater effect on boosting the
Figure 1 Purification and in vitro activity of TAT-SALL4B protein. (a): Schematic diagram of SALL4B construct for TAT-SALL4B fusion protein
expression in insect cells. (b): SDS-PAGE gel picture of Purified TAT-SALL4B, the size of TAT-SALL4B is ~95 KD. (c): Western blots showed
TAT-SALL4B fusion protein could be recognized by SALL4 and or Histidine (His) antibodies. (d): TAT-SALL4B protein regulates Oct4 and SALL4
promoter activities as showed in a luciferase report assay. Protein concentrations were 5 nM (OCT4 promoter) and 10 nM (SALL4-promoter)
separately. WT RLA was standardized to 1. (e): The inhibitory effect of TAT-SALL4B protein on SALL4 promoter activity is dose dependent.
Note: Fold changes compared to WT were labeled on top of the diagrams. RLA: Relative Luciferase Activity; WT: Wide Type. (f): TAT-SALL4B
protein promotes the proliferation of mouse LSK cells in culture.
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pared to G-CSF (Figure 3b). To further confirm our cell
count data, we analyzed the histological sections from
the various treatment groups 8 days after irradiation.
In contrast to the PBS group, in which there were
only very few cells, mainly marrow stromal cells left
in mouse bone marrow cavity, the cellularity of the
bone marrow was dramatically enhanced by SALL4B
treatment, similar to that in the G-CSF treated animals
(Figure 3c). Furthermore, we detected the existence of
TAT-SALL4B in the bone marrow cells of mice by flow
cytometry and immunofluorescent staining (Additional
file 1: Figure S1). This demonstrated the cells that re-
populating the marrow cavity were actively expressing
the TAT-SALL4B protein. An additional control with
TAT-GFP was used to exclude the possibility that the
observed mouse bone marrow regeneration would have
resulted from an effect of TAT. We expressed and puri-
fied TAT-GFP fusion protein using the same method
utilized for TAT-SALL4B and compared the function
of TAT-GFP to PBS in lethally irradiated mice. The re-
sults showed that there was no difference in the totalnumber of bone marrow cells between the two groups
(Additional file 1: Figure S2) suggesting TAT had no
impact on the proliferation of bone marrow cells, and
the SALL4B portion of the fusion protein accounted
for the regeneration of mouse bone marrow.
Radioprotection by TAT-SALL4B
To determine if the enhanced growth of residual marrow
cells had a functional impact, we performed an animal
survival assay after lethal irradiation. TAT-SALL4B treat-
ment significantly increased the survival of mice 24 hours
after 8 Gy lethal irradiation, a dose by which the mouse
usually dies within 30 days. As depicted in Figure 3d, the
cumulative actuarial 30-day survival rate in SALL4B is
85.7%, compared to 0% in the PBS control group. These
data were consistent with the previous observation of
improved bone marrow cellularity in TAT-SALL4B treated
mice. An interesting note is that this radioprotection
effect was achieved by post-irradiation administration
of SALL4B, which is different from G-CSF treatments
where radioprotection is effective only by administration
before or within two hours after irradiation injury [23].
Figure 3 TAT-SALL4B treatment increases the bone marrow
regeneration and survival in lethally irradiated mice.
(a): Strategy of irradiation and injection for bone marrow
regeneration assay. (b): Total bone marrow cell counts (n = 8).
(c): Histological staining of bone sections shows drastically
enhanced cellularity of bone marrow in SALL4B and G-CSF group as
compared to PBS or WT control. (d): Survival curve of lethally irradiated
mice after 7 days treatment of TAT-SALL4B (n = 7) or PBS (n = 10).
Figure 2 SALL4 expression in bone marrow recovery. (a): H&E
stain sections of bone marrows from Control (non-irradiated mice)
or 3 days and 6 days post-sublethally irradiated mice. (b) SALL4 ex-
pression levels by RT-PCR correlate with bone marrow cellularity
seen in the top (n = 3).
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marrow
We then investigated the impact of TAT-SALL4B on the
expansion of residual HSCs/HPCs in detail after abla-
tion. Compared to the control group (0.94 ± 0.24%), LSK
cell percentage was significantly higher in the G-CSF
group (3.29 ± 0.62%). More importantly, the LSK cell
percentage in the SALL4B group (5.52 ± 1.02%) was even
higher than that in the G-CSF group (Figure 4a,b). The
total fold increases (vs. control) of HSCs number
(Whole BM number times LSK%) in mouse bone mar-
row were ~10 fold and ~30 fold in the G-CSF and
SALL4B treated group, respectively (Figure 4c).
In order to analyze the number of progenitor cells in
these bone marrow cell populations, CFC assays were
conducted. In parallel with flow cytometry (data not
shown), both G-CSF- and TAT-SALL4B-treated mice
showed significantly higher bone marrow CFC content
than mice treated with PBS and the G-CSF-treated
mice had the highest bone marrow CFC content overall
(Figure 4d). This is consistent with the observation of a
biased effect by G-CSF toward lineage-restricted pro-
genitors [22].
TAT-SALL4B treatment increases short-term engraftment
in HSCT
One major disadvantage of using human cord blood is
that the absolute number of HSCs/HPCs in hUCB is
much lower than that in bone marrow, which signifi-
cantly delays engraftment [6]. We next tested if TAT-
SALL4B was able to increase the proliferation of trans-
planted donor cells in the host. First, we used the mouse
CD45.1/CD45.2 transplantation system. We enriched
mouse BM precursor cells by c-Kit positive selection
from CD45.1 mice and transplanted into lethally irradi-
ated CD45.2 mice. At day 8, the mice in the SALL4B
group had higher numbers of total bone marrow cells
than those in the control group (2.44 ± 0.36 × 106 vs.
1.58 ± 0.16 × 106; P < 0.05, Figure 5a). When only donor
cells (CD45.1+) were analyzed, the results showed that
the SALL4B group had more donor cells compared to
the controls (1.28 ± 0.21 × 106 vs. 0.78 ± 0.13 × 106; P <
0.05, Figure 5b), although the percentage of donor cells
in the bone marrow was not different between the
SALL4B group and control (data not shown).
In addition, we also tested the effect of the SALL4B
protein on the short-term engraftment of human cord
blood CD34+ cells when introduced into sublethally ir-
radiated NOD/SCID mice. In parallel to the results from
the CD45.1/CD45.2 transplantation system, the total
number of bone marrow cells was significantly increased
at 14 days after transplantation in the SALL4B treated
animals compared to the PBS controls (12.5 ± 1.50 × 106
vs. 5.67 ± 0.94 × 106; P < 0.05, Figure 5c). Furthermore,
Figure 4 TAT-SALL4B augments the content of hematopoietic precursor cells in bone marrow. (a): Representative pictures from flow
cytometry analysis of LSK cell in bone marrow. Note: The diagraphs presented were from Lin- cells, the listed LSK percentages is calculated to the
whole bone marrow cell (both Lin + and Lin- cells included). (b): The percentage of LSK cell in bone marrow TAT-S4LLB treated animals is significant
higher than G-CSF and PBS control group (n = 5). (c): Fold increase of bone marrow LSK cell in G-CSF and SALL4B group compared to control
(n = 5). (d): CFCs numbers using whole bone marrow cells of PBS, G-CSF or SALL4B treated mice (n = 3).
Liao et al. Journal of Hematology & Oncology 2013, 6:84 Page 5 of 11
http://www.jhoonline.org/content/6/1/84the percentage of human cells as identified by human
CD45 antibody in mouse bone marrow of SALL4B pro-
tein treated mice was greater than that of control, al-
though this was not statistically significant (0.15 ± 0.11%
vs. 0.085 ± 0.05% , P = 0.07, Additional file 1: Figure S3).
However, when the total increase of whole bone marrow
cells is taken into account, the increase of human CD45+
cells in the bone marrow is statistically significant in
the SALL4B group when compared to controls (16.6 ±
10.2 × 103 vs. 4.65 ± 2.45 × 103; P < 0.05, Figure 5d).
These data prove that TAT-SALL4B treatment can
promote proliferation of the host mouse bone marrow
not only in a myeloablative condition (lethal irradiation)
but also in a non-myeloablative condition (sublethal ir-
radiation). Also, TAT-SALL4B can enhance the prolifera-
tion of donor cells after transplantation. Recent studies
have shown that homing is an important mechanism for
the increase of donor cell number in transplantation
studies. In order to evaluate if the SALL4B protein hasan effect on the homing activity of donor cells, we con-
ducted further experiments using the CD45.1/CD45.2
transplantation system. In these trials, the recipient mice
were intraperitoneally injected once with TAT-SALL4B
after transplantation then sacrificed 24 hours later for
analysis. Our results showed that there is no difference
regarding the total number of bone marrow cells and
donor cells between the SALL4B treated and control
groups (Additional file 1: Figure S4). Therefore, we be-
lieve that the increased short-term engraftment in both
the mouse-mouse and human-mouse transplantation
studies was most likely related to the expansion of donor
cells in the host and not their homing activity
TAT-SALL4B injection enhances long-term repopulating
capacity of human cord blood CD34+ cells in
NOD/SCID mice
Facilitation and maintenance of the long term engraft-
ment of HSCs is of high importance in HSCT, which
Figure 5 TAT-SALL4B treatment increases the short-term engraftment of mouse or human cells in transplantation. 400,000 c-kit positive
bone marrow cells of CD45.1 B6/SJL mice were injected to lethally irradiated CD45.2 C57BL/6 mice, TAT-SALL4B injection augmented the total
bone marrow (a) and donor CD45.1 cell numbers (b) in the recipient mice (n = 3). Similar results were observed in transplantation of human CB
CD34+ cells into NOD/SCID mice. The total bone marrow cell number (c) and human CD45+ cells (d) in NOD/SCID mice were increased by
TAT-SALL4B protein treatment (n = 4).
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tion and clinical outcome in patients after HSCT. We
have observed that the TAT-SALL4B protein was able to
increase the short-term engraftment of donor cells in
both the mouse-to-mouse and human-to-mouse trans-
plantation models. To address whether post-transplant
administration of TAT-SALL4B is also capable of facili-
tating the long term engraftment of human HSCs,
NOD/SCID mice were injected with human cord blood
CD34+ cells via tail vein (Figure 6a). and received TAT-
SALL4B or PBS intraperitoneally. Sixteen weeks after
transplantation, there was a significant higher percentage
of human CD45+ cells in the bone marrow of TAT-
SALL4B treated mice compared to the control group
(3.90 ± 0.36% vs. 0.43 ± 0.34%, P < 0.05, Figure 6b,c). Fur-
thermore, these cells were able to differentiate in vivo
into various blood lineages including lymphoid, myeloid,
and erythroid lineages (Figure 6d,e). Of note is that
SALL4B protein treatment may be able to reverse the
higher lymphoid (versus myeloid) reconstitution usually
observed in human cord blood HSCs transplantation in
NOD/SCID mice [24]. This demonstrated that the TAT-
SALL4B treatment does not alter the normal differenti-
ation program of human HSCs in vivo and is consistent
with our previous results using SALL4B over-expressed
HSCs/HPCs by lentivirus transduction.
In order to determine if SALL4B protein could also
affect tissues other than hematopoietic cells, we exam-
ined all of the major organs and found there were
no any abnormalities by histology studies (data notshown). We also performed long-term follow up in a
small number of mice receiving TAT-SALL4B post
transplants. As shown in Additional file 1: Table SI, we
monitored the animals throughout the study for body
weight and hematopoietic parameters. No tumors oc-
curred in different strains including C57Bl/6, B6/SJL
and NOD/SCID. Some mice have been observed for
more than 18 months since TAT-SALL4B administra-
tion with no tumor formation.
N-terminal 12 amino acids are essential for SALL4B to
stimulate the expansion of HSCs/HPCs
DNMT mediated epigenetic modifications are important
for the self-renewal of hematopoietic stem cells. We have
found that SALL4 actively recruits DNMT epigenetic
modifiers (DNMT1, 3A, 3B, 3 L and MBD2) to target
genes and leads to their inactivation. Downregulation of
endogenous SALL4 expression led to accelerated cell
differentiation of HSCs/HPCs [17]. Our previous studies
also indicate that the SALL4 N-terminal sequence is
essential for its interactions with DNMTs [25]. We con-
ducted studies to further illustrate that the SALL4 N-
terminal sequence is essential for its interactions with
DNMTs. We generated an N-terminal 12 amino acid (aas)
(N12) deleted SALL4B lentivirus construct (ΔN12-
SALL4B) (Figure 7a). Deletion of the N-12 amino acids
(aas) in SALL4B (ΔN12-SALL4B) strikingly diminished its
physical interactions with DNMTs in mouse LSK cells
resulting in a reduction of methyltransferase activity to a
level that was comparable with that of a negative control
Figure 7 Deletion of the N-12 aas markedly reduces SALL4B mediated LSK cell expansion. (a) Full length (FL) and N-terminal 12 aas de-
leted (δΝ12) SALL4B protein. (b) N-12 aas are essential for recruiting DNMT activities. (c) IP in LSK cells shows N-12 aas are required for SALL4B/
DNMT1 interaction. (d) Growth curve of mouse LSK cells transduced with FL-SALL4B, δΝ12-SALL4B or GFP lentivirus construct.
Figure 6 TAT-SALL4B enhances the long-term engraftment of human cord blood CD34+ cells in NOD/SCID mice. (a): 20,000 human cord
blood CD34+ cells were transplanted into NOD/SCID mice 24 hours after sublethal irradiation (2.5 Gy). Mice were treated with 2 μg TAT-SALL4B
protein or PBS for 2 weeks (daily for the first week and once every other day for the second week). (b): Percentages of human CD45+ cells in
mouse bone marrow at sixteen weeks after transplantation in PBS and SALL4B treated group (n = 3). (c): Representative flow cytometry results of
human CD45+ cell percentage in mouse bone marrow. (d): Representative multilineage differentiation of long-term engrafted human cells in
NOD/SCID mouse. (e): Percentages of lymphoid, myeloid and erythroid lineage from human donor cells.
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HSC/HPC cells, it strikingly diminished the induction of
HSC/HPC expansion unlike the SALL4B (Figure 7d).
Discussion
Recently, we have demonstrated that bone marrow HSC/
HPC transduced to express SALL4A or SALL4B are able
to achieve high levels of ex vivo expansion without loss of
their long-term engraftment capability. To evaluate the
in vivo effect of SALL4 on the expansion of hematopoietic
precusor cells in transplantion, we generated a CPP
SALL4B fusion construct, TAT-SALL4B and expressed it
in insect cells. Protein transduction utilizing CPP might
overcome the limitations of lentiviral vectors, and has re-
cently been in wide use [26-28]. There are multiple phase
2 clinical trials using the CPP approach as a systemic or
topical delivery system and these include NCT00451256
for c-myc (prevention of undesirable cell proliferation in
coronary artery bypass grafts) and PsorBan for cyclospor-
ine andmNCT007885954 for a PKCδ inhibitor (the treat-
ment of acute myocardial infarction).
We found that TAT-SALL4B was able to enhance the
hUCB HSC/HPC engraftment in NOD/SCID. In our
study, after treated with TAT-SALL4B protein, both
short-term and long-term engraftment of human cells
were significantly enhanced in hUCB CD34+ cell trans-
planted NOD/SCID mice. Notably, for short-term en-
graftment, although the percentage of human cells in
mouse bone marrow did not show much difference be-
tween SALL4B and PBS treated animals, the absolute
number of human cells was significantly increased after
SALL4B treatment. Our studies indicate that the in-
creased engraftment (absolute number of human cells)
was likely a result of the direct expansion of donor cells
in bone marrow by SALL4B treatment rather than en-
hanced homing of donor cells.
Interestingly, even though as low as 20,000 human CB
CD34+ cells were used for the transplantation, at
4 months after transplantation, there were still a signifi-
cant portion of human cells existing in the bone marrow
of SALL4B treated mice as compared to almost no hu-
man cells for the control. Our results may have some
therapeutic value in term of the low dose of stem cells
in human UCB transplantation. Numerous clinical stud-
ies have consistently demonstrated that the total nucle-
ated cell (TNC) and CD34+ cell doses in cord blood
grafts are highly correlated with the rate of neutrophil
and platelet engraftment, as well as the incidence of
graft failure and early transplant-related complication
[8]. Because of this, only ~10% of all cord blood speci-
mens can be currently used. It is possible that the intro-
duction of SALL4B to previously unusable cord blood
units due to low TNC or CD34+ cell counts may be
used in future therapies.Drugs which promote rapid hematopoietic recovery
would address the major cause of morbidity and mortal-
ity. G-CSF or derived drugs target specifically the
hematopoietic system and prolong the median survival
time of lethally irradiated mice [23]. However, no sur-
vival advantage is observed when mice receive G-CSF
24 hour’s post-TBI [23]. An increased time window after
TBI would be advantageous in a nuclear emergency set-
ting where healthcare provider times may be at a pre-
mium and they cannot administrate patients right away.
In our study, we found that SALL4B injection dramatic-
ally regenerated the bone marrow in mice after irradi-
ation, suggesting the potential radioprotective effect of
SALL4B. In addition, this effect is achieved by injection
24 hour post-irradiation. Additionally, the TAT-SALL4
could potentially be used for increasing the therapeutic
index of radiation therapy regimens for cancer patients
by reducing the hematologic toxicity of ionizing radi-
ation, enhancing bone marrow stem cell engraftment,
and treatment of aplastic anemia.
Our studies also observed the stimulatory effect of
SALL4B on bone marrow cells in both lethal and sub-
lethal irradiation in mice. Since the bone marrow cell
numbers are not obviously affected in wild type animals
receiving SALL4B treatment (Additional file 1: Figure S2),
this suggests that SALL4B protein may only boost the pro-
liferation of bone marrow cells in pathological conditions
when the bone marrow microenvironment allows more
cells' occupation for the recovery. When the bone mar-
row recovers to a normal condition, the SALL4B will
not cause a hyper-proliferation problem which is re-
lated to tumorigenesis. This is very important for safety
issues. In fact, in order to address the concerns about
safety, we monitored the animals throughout the study
for body weight and hematopoietic parameters. No tu-
mors occurred so far in different strains including
C57Bl/6, B6/SJL and NOD/SCID, and the longest time
since mice received SALL4B is over 18 months.
The mechanism underlying the stimulating effects on
HSC/HPC expansion is still largely unknown. SALL4 is
highly expressed and plays an important role in embry-
onic stem cells, primitive germ cells, HSCs/HPCs and
acute leukemia [17,19,20,29]. Aside from the gatekeeper
role in embryonic development and pluripotency of
inner cell mass in blastocyst [19,20,30,31], SALL4 is es-
sential for primordial germ cell survival [32]. Recent
studies have suggested that hematopoiesis may be initi-
ated from migrating germ cells [33,34] and SALL4 as a
stem cell marker could be useful in further investigating
this notion. Recently, we have found that SALL4 actively
recruits DNMT epigenetic modifiers to target genes and
lead to their inactivation. We further demonstrated that
the N-terminal 12 amino acids were critical for SALL4B
binding to DNMTs and the consequent expansion of
Liao et al. Journal of Hematology & Oncology 2013, 6:84 Page 9 of 11
http://www.jhoonline.org/content/6/1/84HSCs in vitro. In the future, we will explore to shorten
the protein based on these results and test their activity
in in vivo expansion of bone marrow stem cells. In
addition, bone marrow niche cells such as endothelial
and perivascular cells [35] may also uptake TAT-SALL4B
protein and contribute to the in vivo expansion of
HSCs/HPCs in present study.
In conclusion, our data demonstrated that TAT-SALL4B
protein from insect cells promoted hematopoietic recovery
after lethal and sub-lethal irradiation. Furthermore, TAT-
SALL4B treatment was able to enhance both the short-
term and long-term engraftment of human UCB cells in
NOD/SCID mice and the mechanism is likely related to
the in vivo expansion of donor and recipient cells in the
bone marrow. TAT-SALL4B protein could become an at-
tractive candidate to enhance the engraftment of human
UCB cells in hematopoietic stem cells transplantation and
facilitate the hematopoietic recovery after radiation injury.
Material and methods
Purification of TAT-SALL4B
Sf9 insect cells (ATCC, Manassas, VA, USA) were trans-
fected with a baculovirus expression construct contain-
ing either the human SALL4B sequence, or a GFP
control, each with a c-terminal 6x His fusion tag. To re-
cover recombinant protein, cells were lysed in lysis buf-
fer [50 mM Na2HPO4/NaH2PO4 (pH 7.4), 300 mM
NaCl, 20 mM NEM, 0.2% Triton X-100] containing
20 mM imidazole. His-tagged proteins were eluted in
the lysis buffer containing 300 mM imidazole and blot-
ted for detection with SALL4 or GFP antibody. Fractions
containing the desired protein were pooled and dialyzed
in IMDM overnight.
Promoter assay
Promoter luciferase assays were performed with the Dual-
Luciferase Reporter Assay System (Promega, Madison,WI,
USA) as described previously [20]. Briefly, MCF-7 cells
were transfected with the SALL4B or OCT4 promoter
reporter plasmid [20] using Lipofectamine 2000 (Invi-
trogen, Grand Island, NY, USA). Five hours later, cells
were changed to fresh medium and TAT-SALL4B pro-
teins or BSA were added. The next day, cells were ana-
lyzed after treated with TAT-SALL4B Protein or BSA
for 3 times. The data are represented as the ratio of
firefly to Renilla luciferase activity (Fluc/Rluc). These
experiments were performed in duplicate.
Animals
Animals used includes three different strains C57BL/6
(CD45.2), B6/SJL (CD45.1) and NOD/SCID mouse (The
Jackson Laboratory, Bar Harbor, ME, USA). All animal
procedures were approved by Stony Brook University
Institutional Animal Care and Use Committee.Cell culture
Bone marrow cells were collected from C57BL/6 mice
femur and tibia and magnetically sorted with Lineage, c-
Kit and Sca-1 labeling kits from MACS (Miltenyi Biotec,
Auburn, CA, USA) and cultured in DMEM supple-
mented with 10% FBS, 100 ng/ml mSCF, 6 ng/ml mIL-3
and 10 ng/ml hIL-6 (ProSpec, Rehovot, Israel). LSK
(lineage-/c-Kit+/Sca-1) cells were plated in 24-well at
100,000 cells/well and treated with 20 nM TAT-SALL4B
or BSA daily. Cells were counted every day for 6 days. In
another experiment. the LSK cells were infected with
full-length SALL4B, N-terminal 12 amino acids deleted
SALL4B (ΔN12-SALL4B) or GFP lentiviruses overnight
for 12–15 hours then recovered in culture medium.
Bone marrow recovery analysis and survival test
Eight week old C57BL/6 mice received 7 Gy total body
irradiation (TBI) at dose of 0.6 Gy/min. Twenty four
hours later, 6 μg TAT-SALL4B protein, 2 μg G-CSF (as
previously described [22]), 6 μg TAT-GFP protein or
PBS was injected intraperitoneally daily for seven days.
At day 8, bone marrow cells were counted and analyzed
by flow cytometry. In addition, bone marrow tissue sec-
tions were prepared for Wright-Giemsa staining. For
survival test, mice were given a single dose of 8 Gy TBI
and received TAT-SALL4B or PBS in same pattern as
mentioned above. Mice were monitored daily after ir-
radiation for 30 days.
Cell transplantation
There are two transplantation models utilized in our study:
CD45.1/CD45.2 (mouse to mouse) and CD34+/NOD/SCID
(human to mouse) models. Animals received 7 Gy TBI for
C57BL/6 mice or 2.5 Gy TBI for NOD/SCID mice. 24 hours
after irradiation, animal were injected with mouse 400,000
c-Kit + or 40,000 human CB CD34+ cells. For short-term
engraftment analysis, transplanted mice were given 7 con-
secutive TAT-SALL4B protein or PBS injections for seven
days. At day 8 or day 14, total bone marrow cells were
counted and the donor cells in recipient mice were ana-
lyzed using mouse CD45.1 or human CD45 antibody. For
long-term engraftment experiment, 20,000 human CB
CD34+ cells were transplanted into NOD/SCD mice and 4
additional injections of proteins were conducted in the fol-
lowing week. Human cell content in the bone marrow was
checked 16 weeks after transplantation.
Homing assay
CD45.2 mice were irradiated (7 Gy) and transplanted
with 400,000 CD45.1 mouse bone marrow c-Kit + cells
24 hours later. TAT-SALL4B protein or PBS was injected
into CD45.2 mice right after transplantation. Animals
were sacrificed for bone marrow cell collection 24 hours
after transplantation. The percentage of CD45.1 cells in
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the absolute number of CD45.1 cells was calculated.
CFC assay
20,000 bone marrow cells from TAT-SALL4B, G-CSF or
PBS treated animals were suspended in MethoCult®
(Stemcell Technologies) medium for CFC assay accord-
ing manufacturer's instruction. A colony with more than
100 cells was counted as a positive colony.
Flow cytometry
Phycoerythrin (PE), Fluorescein isothiocyanate (FITC),
allophycocyanin (APC), or PerCP-Cy5.5-conjugated anti-
bodies to human CD34, CD19, CD38,CD15, CD33,
CD45, CD3 or mouse CD45.1, CD45.2, Lineage, Sca-1,
c-Kit (BD Biosciences, San Jose, CA, USA) were used for
flow cytometry analysis. Isotype control antibodies were
used for compensating and gating when setting up the
flow cytometer for each analysis.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) analyses were per-
formed as reported previeously [20]. The primer sets for
SALL4 were Forward: GCAGCCTCAGCAGCTACC,
Reverse: GGGAGTTCACTGGAGCAC; and GAPDH
were: Forward: ATACGGCTACAGCAACAGGG, Re-
verse: GCCTCTCTTGCTCAGTGTCC.
Immunoprecipitation
HEK 293 cells were infected with Flag tagged SALL4B or
ΔN12SALL4B lentivirus. Proteins were prepared with Cel-
Lytic™ MT Cell Lysis Reagent (Sigma-Aldrich, St Louis,
MO, USA). Immunoprecipitations were performed by
using Dynabeads® Protein G Immunoprecipitation Kit (Invi-
trogen) according to manufacturer’s instructions. Western
blots were conducted with antibodies against Flag (Bethyl
Laboratories, Montgomery, TX, USA) and DNMT1 (Novus
Biologicals, Littleton, CO, USA).
DNA methyltransferase activity assay
These experiments were carried out using the EpiQuik
DNMT Activity/Inhibition Assay Ultra Kit (Epigentek,
Farmingdale, NY, USA) following the manufacturer’s
procedures. Firstly, nuclear proteins were extracted from
tested cells using the EpiQuik™ Nuclear Extraction Kit
(Epigentek). For immunoprecipitations preceding the as-
says, we used antibodies against HA or IgG control from
Bethyl Laboratories.
Statistical analysis
Results are reported as means ± SD. Values with P <0.05
were considered to be statistically significant.Additional file
Additional file 1: Table S1. Follow-up irradiated mice receiving
TAT-SALL4B protein post-transplant.
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